PeptiDream appoints Dr Kiyofumi Kaneshiro to management team
12 January 2018 -

PeptiDream Inc (TYO: 4587) has appointed Dr Kiyofumi Kaneshiro to its management team, the Japanese biopharmaceutical company announced on Friday.

Dr Kaneshiro brings a wealth of experience, with his previous role seeing him serve as a partner and managing director at The Boston Consulting Group (BCG).

During his time at BCG, Dr Kaneshiro worked with clients in the pharmaceutical and medtech sectors and led corporate growth strategy development, M&A strategy development, new business launch and R&D productivity.

As executive vice president at PeptiDream, Dr Kaneshiro will work with president & CEO Dr Patrick C. Reid and executive VP Dr Keiichi Masuya to manage and direct all scientific, strategic and business efforts.

Discussing Dr Kaneshiro's appointment, Dr Reid said his range of abilities and experience would help guide PeptiDream toward its business and strategic objectives as the company enters the next phase of growth.